Premium
Round robin test on quantification of amyloid‐β 1–42 in cerebrospinal fluid by mass spectrometry
Author(s) -
Pannee Josef,
Gobom Johan,
Shaw Leslie M.,
Korecka Magdalena,
Chambers Erin E.,
Lame Mary,
Jenkins Rand,
Mylott William,
Carrillo Maria C.,
Zegers Ingrid,
Zetterberg Henrik,
Blennow Kaj,
Portelius Erik
Publication year - 2016
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2015.06.1890
Subject(s) - cerebrospinal fluid , chromatography , liquid chromatography–mass spectrometry , mass spectrometry , tandem mass spectrometry , chemistry , medicine , pathology
Cerebrospinal fluid (CSF) amyloid‐β 1–42 (Aβ 42 ) is an important biomarker for Alzheimer's disease, both in diagnostics and to monitor disease‐modifying therapies. However, there is a great need for standardization of methods used for quantification. To overcome problems associated with immunoassays, liquid chromatography‐tandem mass spectrometry (LC‐MS/MS) has emerged as a critical orthogonal alternative. Methods We compared results for CSF Aβ 42 quantification in a round robin study performed in four laboratories using similar sample preparation methods and LC‐MS instrumentation. Results The LC‐MS results showed excellent correlation between laboratories ( r 2 >0.98), high analytical precision, and good correlation with enzyme‐linked immunosorbent assay ( r 2 >0.85). The use of a common reference sample further decreased interlaboratory variation. Discussion Our results indicate that LC‐MS is suitable for absolute quantification of Aβ 42 in CSF and highlight the importance of developing a certified reference material.